US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Read More
Tag: Novimmune
Novimmune submits lead drug emapalumab in Europe
Swiss biotech Novimmune has submitted a marketing application in Europe seeking permission to market its lead compound emapalumab for the treatment of patients with primary Hemophagocytic Lymphohistiocytosis (HLH).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
